NCT05921110 (PENG) is a NA clinical trial of Pericapsular nerve group block 0,25% in Hip Fractures, sponsored by Ilker Ital.

Who is sponsoring NCT05921110?

NCT05921110 is sponsored by Ilker Ital.

What drugs are being tested in NCT05921110?

Interventions in NCT05921110: Pericapsular nerve group block 0,25%, Pericapsular nerve group block 0,16%.

What condition does NCT05921110 study?

NCT05921110 studies Hip Fractures, Postoperative Pain.

Is NCT05921110 still recruiting?

NCT05921110 is currently status unknown. Last updated 27 June 2023.

Last reviewed 2023-06-27 · How we verify

NCT05921110: PENG

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Evaluation of the Effectiviness of Two Different Bupivacaine Concentrations of the Pericapsular Nerve Group (PENG) Block

Status unknown NA Last updated 27 June 2023

What this trial tests

NA trial testing Pericapsular nerve group block 0,25% in Hip Fractures in 66 participants. Status unknown.

Timeline

15 May 2023

Primary endpoint
30 November 2023

30 November 2023

Quick facts

Lead sponsor	Ilker Ital
Phase	NA
Status	Status unknown
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	double
Primary purpose	treatment
Enrollment	66
Start date	15 May 2023
Primary completion	30 November 2023
Estimated completion	30 November 2023
Sites	2 locations across Turkey (Türkiye)

Drugs / interventions tested

Pericapsular nerve group block 0,25%
Pericapsular nerve group block 0,16%

Conditions studied

Hip Fractures — all drugs for Hip Fractures →
Postoperative Pain — all drugs for Postoperative Pain →

Sponsor

Ilker Ital

Who can join

Adults 18 to 85, any sex, with Hip Fractures or Postoperative Pain. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The use of regional anaesthesia techniques as part of multimodal analgesia in hip surgeries improves postoperative analgesia. PENG (Pericapsular nerve group) block is an effective motor sparing analgesia technique used in hip surgeries. The purpose of this study was to assess the efficacy of PENG block in terms of analgesic requirements and pain density in patients undergoing hip surgery, using two different concentrations of local anaesthetic.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other recruiting trials for Hip Fractures

Currently open trials in the same condition.

NCT07239817 — PENG Block + LIA For Endoprosthesis Surgery With Anterior Approach · NA · recruiting
NCT07002723 — Effects of Esketamine Combined With Dexmedetomidine on Postoperative Sleep Quality · NA · recruiting
NCT06893406 — Cervical Myelopathy in Hip Fracture Patients · NA · recruiting
NCT06565910 — Bupivacaine Liposome Plus Bupivacaine or Ropivacaine for Pericapsular Nerve Group Block in Hip Arthroplasty (PENG) · Phase 4 · recruiting
NCT06455813 — What Laxative Should be Used After Hip Fracture Surgery? · Phase 4 · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT05921110 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Ilker Ital
Last refreshed: 27 June 2023

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05921110.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing